SCHEMBL5131385

SCHEMBL5131385

N[C@@H]([CH]CNCc1cccc(-c2ccccn2)c1)Cc1cc(F)cc(F)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HIF1A Q16665 3/20 0.36
AURKA O14965 1/20 0.34
FFAR1 O14842 1/20 0.34
CETP P11597 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
PGGT1B P53609 1/20 0.33
NTRK1 P04629 1/20 0.33
GRM5 P41594 2/20 0.33
SLC6A9 P48067 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
MAP4K4 O95819 1/20 0.32
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5131389 0.82 KDM4E (0.41) HRH3CTSLCTSBCTSSKDM4E
SCHEMBL5131863 0.78 BACE1 (0.41) CTSB
SCHEMBL5130264 0.78 BACE1 (0.45) HIF1ANOS1
SCHEMBL6170397 0.78 BACE1 (0.41) CTSB
SCHEMBL18129033 0.70 MAP4K4 (0.55) HRH3CTSLCTSBCTSSHIF1A
SCHEMBL5117521 0.67 HTR2A (0.50) FFAR1
SCHEMBL18129023 0.67 MAP4K4 (0.53) HRH3CTSLCTSBCTSSHIF1A
SCHEMBL7404655 0.66 HRH3 (0.54) HRH3CTSLCTSBCTSSKDM4E
SCHEMBL2696099 0.66 HRH3 (0.56) HRH3KDM4EHIF1AFFAR1NOS3
SCHEMBL29793738 0.66 HRH3 (0.56) HRH3KDM4EHIF1AFFAR1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 HRH3 2360/4885CTSL 77/4885CTSB 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.